Propanc Biopharma Inc.
PPCB | NASDAQ
$1.91
+$0.07 (+3.80%)
Nov 2, 2026, 9:45 AM ET · Market open
Fiscal Year Period Ending | FY 2026 Jun 30, 2026 | FY 2025 Jun 30, 2025 | FY 2024 Jun 30, 2024 | FY 2023 Jun 30, 2023 | FY 2022 Jun 30, 2022 | FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -18.19M | -57.28M | -1.54M | -1.78M | -1.99M | -1.81M |
Interest Income | 161 | 9 | 60 | 36 | 5.61K | n/a |
Pretax Income | -18.86M | -58.92M | -1.95M | -2.79M | -2.71M | -2.14M |
Net Income | -18.86M | -58.92M | -1.82M | -2.66M | -2.66M | -2.03M |
Selling & General & Admin | 17.56M | 57.05M | 1.29M | 1.5M | 1.71M | 1.58M |
Research & Development | 625.48K | 223.72K | 248.1K | 247.92K | 256.05K | 230.96K |
Other Expenses | n/a | n/a | n/a | 28.84K | 28.37K | n/a |
Operating Expenses | 18.19M | 57.28M | 1.54M | 1.78M | 1.99M | 1.81M |
Interest Expense | 430.54K | 563.76K | 665.84K | 532.82K | 568.8K | 449.46K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 18.19M | 57.28M | 1.54M | 1.78M | 1.99M | 1.81M |
Income Tax Expense | n/a | n/a | -129.13K | -129.84K | -54.98K | -113K |
Shares Outstanding (Basic) | 112.37K | 15.87K | 85.05M | 0.12 | 0 | 0 |
Shares Outstanding (Diluted) | 112.37K | 15.87K | 85.05M | 0.12 | 0 | 0 |
EPS (Basic) | -176.16 | -3.71K | -0.02 | -26.97M | -738.45M | -11.96B |
EPS (Diluted) | -176.16 | -3.71K | -0.02 | -26.97M | -738.45M | -11.96B |
EBITDA | -18.41M | -58.34M | -1.26M | -2.26M | -2.14M | -1.69M |
EBIT | -18.43M | -58.36M | -1.28M | -2.26M | -2.14M | -1.69M |
Depreciation & Amortization | 22.7K | 20.19K | 21.66K | 1.67K | 1.99K | 1.99K |
Add to Watchlist
Select watchlists to add or remove PPCB